Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1339747 | 1.00 | NPC1 (0.41) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL905572 | 1.00 | NPC1 (0.41) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| Toluene SCHEMBL31547896 | 0.88 | NPC1 (0.50) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL538187 | 0.79 | NPC1 (0.39) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL17368455 | 0.78 | NPC1 (0.45) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL3672958 | 0.77 | NPC1 (0.41) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL5324109 | 0.74 | NPC1 (0.47) | NPC1RAB9AKMT2AALDH1A1KDM4E | |
| SCHEMBL41312 | 0.73 | — | — | |
| Phosphine SCHEMBL14798918 | 0.71 | — | — | |
| Ammonia Solution, Strong SCHEMBL18170218 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003097706-A1 | POLYAMPHOLYTES | NOVOSOM AG (DE) | 2003-11-27 | — | — | WO | claimed |
| US-12097475-B2 | Microfluidic system | THE UNIVERSITY OF CHICAGO (US) | 2024-09-24 | — | — | US | disclosed |
| US-20240192707-A1 | MICROFLUIDIC SYSTEM | THE UNIVERSITY OF CHICAGO | 2024-06-13 | — | — | US | disclosed |
| US-20240160231-A1 | MICROFLUIDIC SYSTEM | THE UNIVERSITY OF CHICAGO | 2024-05-16 | — | — | US | disclosed |
| US-11853087-B2 | Microfluidic system | THE UNIVERSITY OF CHICAGO (US) | 2023-12-26 | — | — | US | disclosed |
| US-11478799-B2 | Method for conducting reactions involving biological molecules in plugs in a microfluidic system | THE UNIVERSITY OF CHICAGO (US) | 2022-10-25 | — | — | US | disclosed |
| EP-2283918-B1 | Device and method for pressure-driven plug transport and reaction | UNIV CHICAGO (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-2282214-B1 | Device and method for pressure-driven plug transport and reaction | UNIV CHICAGO (US) | 2022-10-05 | — | — | EP | disclosed |
| US-11413615-B2 | Device and method for pressure-driven plug transport and reaction | THE UNIVERSITY OF CHICAGO (US) | 2022-08-16 | — | — | US | disclosed |
| US-11413614-B2 | Device and method for pressure-driven plug transport and reaction | THE UNIVERSITY OF CHICAGO (US) | 2022-08-16 | — | — | US | disclosed |
| US-6841684-B2 | For therapy of chronic pain, glaucoma or elevated intraocular pressure and other diseases with substantially reduced cardiovascular or sedative side effects | ALLERGAN, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1104407-B1 | COMPOUNDS AS SELECTIVE AGONISTS AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040220402-A1 | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds | ALLERGAN, INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2004038363-A2 | MICROFLUIDIC DEVICE AND METHOD FOR PRESSURE-DRIVEN PLUG TRANSPORT AND REACTION | THE UNIVERSITY OF CHICAGO (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2003099795-A1 | 4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL-2-ONES AS AGONISTS OF THE ALPHA-2B AND ALPHA-2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030023098-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors | ALLERGAN SALES, INC. | 2003-01-30 | — | — | US | disclosed |
| US-20020156076-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors | ALLERGAN SALES, INC. | 2002-10-24 | — | — | US | disclosed |
| US-6329369-B1 | ANALGESICS FOR TREATING GLAUCOMA OR ELEVATED PRESSURE AND OTHER DISEASES WITH REDUCED SIDE EFFECTS BY TREATING A MAMMAL IN NEED THEREOF AN AGONIST OF ALPHA 2B OR ALPHA 2B/2C ADRENERGIC RECEPTOR | ALLERGAN SALES, INC. | 2001-12-11 | — | — | US | disclosed |
| EP-1104407-A1 | COMPOUNDS AS SELECTIVE AGONISTS AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | Allergan Sales, Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2001000586-A1 | COMPOUNDS AS SELECTIVE AGONISTS AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN SALES, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220402-A1 | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds | ADRB2, ADRA2C, ADRB1 | NPC1 3193/4885RAB9A 3095/4885KMT2A 2123/4885 |
| US-11413615-B2 | Device and method for pressure-driven plug transport and reaction | SLC6A9, SLC6A5, PTGFR | NPC1 115/4885RAB9A 1811/4885KMT2A 4787/4885 |
| US-20030023098-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors | ADRA2B, ADRB2, ADRA2C | NPC1 1160/4885RAB9A 923/4885KMT2A 3278/4885 |
| US-11478799-B2 | Method for conducting reactions involving biological molecules in plugs in a microfluidic system | SLCO4C1, C3AR1, MSN | NPC1 697/4885RAB9A 4114/4885KMT2A 4839/4885 |
| US-20020156076-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors | ADRB2, ADRB1, ADRA2B | NPC1 850/4885RAB9A 3415/4885KMT2A 2126/4885 |
| US-11413614-B2 | Device and method for pressure-driven plug transport and reaction | SLC6A9, SLC6A5, PTGFR | NPC1 115/4885RAB9A 1811/4885KMT2A 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.